Zobrazeno 1 - 10
of 352
pro vyhledávání: '"Eptinezumab"'
Autor:
Charles Argoff, Steven P. Herzog, Ryan M. Smith, Sameer V. Kotak, Liza Sopina, Yvonna Saltarska, Seema Soni-Brahmbhatt, Fawad A. Khan
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Despite recent advancements in migraine treatment, some patients continue to endure significant disease burden. Due to the controlled nature of randomized trials in migraine prevention, many real-world patients with comorbidities
Externí odkaz:
https://doaj.org/article/a59f2aecbfce4cada0da55d02b8bc5df
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Background Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migrai
Externí odkaz:
https://doaj.org/article/fca3cd0fb19d4594a041cd2b7b168b47
Autor:
Linus Jönsson, Susanne F. Awad, Stephane A. Regnier, Brian Talon, Steven Kymes, Xin Ying Lee, Peter J. Goadsby
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality of life (HRQoL) improvement beyond improvements in monthly migraine day (MMD) reduction. Investigations into the co
Externí odkaz:
https://doaj.org/article/7abee575dccc432ea565d608deb6bddf
Autor:
Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 465-473 (2024)
Abstract Introduction The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in
Externí odkaz:
https://doaj.org/article/5a5d294c06a149ed8eaeedc5afe616a2
Autor:
Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 339-353 (2024)
Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across th
Externí odkaz:
https://doaj.org/article/db3613d3bbe843fc9dda99c7098d8dd2
Autor:
Shengyuan Yu, Jiying Zhou, Guogang Luo, Zheman Xiao, Anders Ettrup, Gary Jansson, Ioana Florea, Kristina Ranc, Patricia Pozo-Rosich
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background For some people with migraine, despite taking greater amounts of acute headache medication (AHM), they develop an increase in monthly headache days. This cycle of increasing headache days, and in turn AHM use, can lead to a second
Externí odkaz:
https://doaj.org/article/e9e9d427ec264f7f8d5d53e8c92478ce
Autor:
Abubker Omaer, Abdulrazaq Albilali, Reem Bamogaddam, Fares Almutairi, Raghad Alsaif, Osama Almohammadi, Abdullah A Alhifany
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 4, Pp 101989- (2024)
Background: Migraine is often associated with depression and anxiety, leading to a diminished quality of life. Calcitonin gene‐related peptide (CGRP) antagonists have shown promise in treating migraines, but their effects on concurrent depression a
Externí odkaz:
https://doaj.org/article/6fc1407f310e458981ccd818216edf43
Autor:
Pablo Irimia, Sonia Santos-Lasaosa, Patricia Pozo-Rosich, Rogelio Leira, Julio Pascual, José Miguel Láinez
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Eptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month. Eptinezumab is administered by
Externí odkaz:
https://doaj.org/article/d236da73e51e4ae1bc81feed019f89b1
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 19, Pp 959-971 (2023)
Claudia Altamura,1,2 Nicoletta Brunelli,1,2 Marilena Marcosano,1,2 Alessandro Alesina,1,2 Luisa Fofi,1,2 Fabrizio Vernieri1,2 1Fondazione Policlinico Universitario Campus Bio-Medico, Roma, 00128, Italy; 2Unit of Headache and Neurosonology, Department
Externí odkaz:
https://doaj.org/article/d2233bd3614c4507887e97c20fd02ec0
Autor:
Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi, Cinzia Aurilia
Publikováno v:
Brain Sciences, Vol 14, Iss 7, p 672 (2024)
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-fr
Externí odkaz:
https://doaj.org/article/26eb09c512a54deab40567391b3b856f